Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Orient Pharma Co. Ltd. (4166) operate in?
Orient Pharma Co. Ltd. belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Orient Pharma Co. Ltd. (4166) current stock price?
As of the latest data, Orient Pharma Co. Ltd. stock price is NT$24.50, with a previous close of NT$24.50.
What is Orient Pharma Co. Ltd. (4166) current market capitalization?
Orient Pharma Co. Ltd. market cap is approximately 5.95 billion.
What is Orient Pharma Co. Ltd. (4166) Earnings Per Share (EPS)?
The trailing EPS is NT$0.90.
What is Orient Pharma Co. Ltd. (4166) Price-to-Earnings (P/E) ratio?
Orient Pharma Co. Ltd. current P/E ratio is 27.22.
Does Orient Pharma Co. Ltd. (4166) pay dividends?
No. Orient Pharma Co. Ltd. does not pay a dividend.
What is Orient Pharma Co. Ltd. (4166) beta (volatility) score?
Orient Pharma Co. Ltd. has a beta of 0.086, indicating lower volatility than the overall market.